While recruitment and regulation are improving, they remain pain points, say speakers at Arena International’s OCT West Coast ...

BOSTON, MA, USA I February 19, 2025 I Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered ...

"In many of the countries and regions where first-generation PCABs are launched, these are gradually taking over the market from the proton pump inhibitors (PPIs). Our ambition is to develop a unique ...

Cumberland Pharmaceuticals' antibiotic Vibativ (telavancin) injection has gained approval from China’s National Medical ...

华东医药表示，MediBeacon®TGFR已在美国获批，作为全球首个获批用于肾功能评估的床旁产品，为临床评估肾功能提供了一种有效的测量新选择。本次经皮肾小球滤过率测量设备于中国获批，是MediBeacon®TGFR研发进程中的又一重要进展。

2025年1月8日 ，强生宣布暂停Varipulse在美国的外部评估和商业应用，并称正在调查外部评估中报告的四起患者治疗后发生中风事件的原因。强生在PFA市场已失去先发优势，停售风波更增加了一丝阴云。

"Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust developmen ...

Pharmaceuticals announced the NMPA, National Medical Products Administration, approval of Cumberland’s Vibativ injection in ...

Specialty pharmaceutical companies Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) and SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals" or "SciClone") today announced the NMPA ...

近日，南方+记者从国家药品监督管理局（NMPA）官网获悉，由默沙东（MSD）申报的新型酶抑制剂复合制剂——注射用头孢洛生他唑巴坦钠（商品名：Zerbaxa卓利达）上市申请已获得中国国家药品监督管理局批准。

2月17日，信达生物宣布，PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363获得FDA授予快速通道资格，拟定适应症为抗PD- (L)1免疫检查点抑制剂及含铂化疗治疗后进展的局部晚期或转移性鳞状非小细胞肺癌。

▎药明康德内容团队报道针对自身免疫性疾病的治疗理念正在发生变化，新靶点、新方法和新技术不断涌现。本文将盘点15款有望在2025年获中国国家药监局（NMPA）批准上市的自身免疫性疾病领域新药*，它们覆盖的适应症包括银屑病、类风湿关节炎、特应性皮炎、克罗 ...